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Abstract
Background: Cholesterol gallstone disease is a very common disease in both industrialized and developing
countries. Many studies have found that cholesterol gallstones are more common in women than men. The
molecular mechanisms underlying the relationship between female gallstone disease and hepatic sterol
transporters are still undergoing definition and have not been evaluated in humans.
Aims: The aim of this study is to probe for underlying hepatic molecular defects associated with development of
gallstones in female.
Methods/Results: Fifty-seven nonobese, normolipidemic Chinese female gallstone patients (GS) were investigated
with 12 age- and body mass index-matched female gallstone-free controls (GSF). The bile from the female GS had
higher cholesterol saturation than that from the female GSF. The hepatic NPC1L1 mRNA levels were lower in
female GS, correlated with SREBP2 mRNA. NPC1L1 downregulation was confirmed at protein levels. Consistently,
immunohistochemistry showed decreased NPC1L1 expression in female GS.
Conclusions: The decreased hepatic NPC1L1 levels in female GS might indicate a downregulated reabsorption of
biliary cholesterol in the liver, which, in turn, leads to the cholesterol supersaturation of bile. Our data are
consistent with the possibility that hepatic NPC1L1 may be mediated by SREBP2.
Introduction
Cholesterol gallstone disease is common in both indus-
trialized and developing countries [1,2]. Several clinical
investigations have found an association between the
increased incidence of cholesterol gallstones in China
and a westernization of the traditional Chinese diet
[2-4]. And because of the world-wide obesity epidemic
with insulin resistance being part of the metabolic syn-
drome, the prevalence of cholesterol gallstones seems to
be rising.
As found by epidemiological and clinical studies,
women are twice as likely as men to form cholesterol
gallstones at all ages, and estrogen could be an impor-
tant risk factor for the formation of cholesterol gall-
stones. A large number of human and animal studies
have proposed that estrogen increases the risk of
developing cholesterol gallstones by increasing the hepa-
tic secretion of biliary cholesterol.
Hypersecretion of biliary cholesterol and cholesterol
supersaturation of the bile are considered to be the
most important prerequisites for gallstone formation.
Presently, the pathways for the biliary cholesterol secre-
tion in the liver are incompletely understood. In a pre-
vious study, we observed that Chinese gallstone patients
had an increased hepatic ABCG5/ABCG8 expression
[5]. But study also found no relationship exists between
biliary cholesterol excretion and hepatic ABCG5 and
ABCG8 gene expression in human liver transplantation
patients [6]. The existence of novel mechanisms other
than ABCG5/ABCG8 in regulating biliary cholesterol
secretion has been suggested based on several recent
observations in mice [7,8].
Niemann-Pick C1-like 1(NPC1L1) has been recently
identified as a critical protein for enterohepatic free cho-
lesterol absorption [9-13]. NPC1L1 is widely expressed
in many human tissues, with the highest expression in
small intestine and in the liver [13,14]. Recent studies
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role in the hepatic secretion of cholesterol. Hepatic
overexpression of NPC1L1 in mice significantly
decreases biliary cholesterol concentration [9].
Compared with female gallstone-free controls (GSF),
the metabolic abnormalities underlying the supersatura-
tion of bile and the formation of cholesterol gallstones
in female gallstone patients (GS) are not yet fully under-
stood. In this study, we attempted to identify some of
the molecular defects in hepatic cholesterol and bile
acid metabolism involved in the pathogenesis of choles-
terol gallstone disease in female. Our present results
suggest that in Chinese female GS, supersaturation of
bile is associated with a decreased expression of hepatic
NPC1L1. We also observed that hepatic NPC1L1 may
be mediated by SREBP2.
Materials and methods
Subjects
Fifty-seven Chinese female GS and 12 Chinese female
GSF were included in this study. The female GS under-
went laparoscopic cholecystectomy. Gallbladder size was
evaluated by ultrasonography, and gallbladder function
was assessed by analysis of total biliary lipids. Choles-
terol gallstones were confirmed by visual inspection of
the typical cut-surface of gallstones or, when necessary,
by enzymatic cholesterol analysis. The female GSF
included nine patients with right hepatic hemangioma
and three with early carcinoma of head of pancreas,
who also undergoing cholecystectomy. No gallstones
were found in any of these controls after resection of
the gallbladder, nor were cholesterol crystals found in
bile by polarized light microscopy. None of the patients
had any other disorders affecting hepatic, gastrointest-
inal, renal, and endocrine functions (i.e., either diabetes
mellitus or signs of insulin resistance). None of the
patients were subjected to any lipid-lowering treatment.
Informed consent was obtained from all participants
prior to enrollment in the study, including permission
to collect a liver biopsy. The study protocol was
approved by the ethics committees at the Ruijin Hospi-
tal, Medical School of Shanghai Jiaotong University.
Procedure for sample collection
Patients were fasted overnight before surgery, which
began at 9 AM. After opening the abdomen, or after the
application of pneumoperitoneum, a wedge biopsy
( ~ 0 . 5 - 1 . 0g )w a st a k e nf r o mt h er i g h tl o b eo ft h el i v e r ,
immediately snapfrozen in liquid nitrogen, and stored at
-80°C. Criteria for a functioning gallbladder consisted of
i) the presence of dark concentrated bile in the gallblad-
der and ii) no evidence of impacted stones in the neck
of the cystic duct at operation. After clamping the cystic
duct, bile from the gallbladder was obtained by
aspiration. All of the operations were performed without
any complications. Participation in the study did not
result in prolonged hospitalization, and no serious
adverse events were reported.
Plasma and biliary lipid analyses
Plasma total cholesterol, triglycerides, HDL cholesterol,
apolipoprotein A-I (apoA-I), and apoB were analyzed
with an automated bioanalyzer (Roche Hitachi Modular
P800) and corrected by dilution with the addition of
EDTA (2%). LDL cholesterol in plasma was calculated
according to Friedewald’s equation. Gallbladder bile
cholesterol, phospholipid and total bile salt levels were
measured as described previously [15]. The cholesterol
saturation index (CSI) was calculated using Carey’s criti-
cal table [16].
Relative mRNA quantification
Hepatic total RNA was extracted using Trizol reagent
(Invitrogen, Carlsbad, CA) according to the manufac-
turer’s protocol, and quality was evaluated by measuring
the 260/280-nm absorbance ratio (≥1.8) and by electro-
phoresis. cDNA synthesis was performed with the High-
Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems, Foster City, CA, USA). Real-time quantitative
PCR assays were performed in triplicate using SYBR-
Green (MedProbe, Oslo, Norway). PCR primers (primer
sequences are available on request) were designed using
Primer Express 2.0 (Applied Biosystems, Foster City,
CA, USA), all with sequences crossing exon-exon
boundaries. Data were calculated by the ΔCt method,
expressed in arbitrary units, and normalized to the sig-
nals obtained when the same cDNA was assayed for
Cyclophilin A, selected as endogenous reference gene.
The fold change for each mRNA quantity in the female
GS material was expressed in relation to the obtained
value for female GSF, the mean value of which arbitra-
rily was set at 1.
Western blot analysis
Fifty micrograms of liver membranes from each patient
sample was separated on a 10% SDS-PAGE gel and then
transferred onto nitrocellulose membranes (Invitrogen).
After blocking in 5% nonfat dry milk in PBST (PBS with
0.05% Tween-20), the nitrocellulose membranes were
incubated overnight at 4°C with goat anti-NPC1L1
(1:200; Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA) in 5% nonfat milk powder in PBST. After washing
with PBST, donkey anti-goat IgG antibody was added
(1:2,000; Santa Cruz). The signals were detected using
the SuperSignal chemiluminescence kit (Pierce Biotech-
nology, Inc., Rockford, IL) and a Fuji BAS 1800 analyzer
(Fuji Photo Film Co.) and quantified by ImageJ 1.37
http://rsb.info.nih.gov/ij. After cleaning the membranes
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GAPDH (1:5,000; Kangchen Biotech, Shanghai, China)
as a loading control. Data are expressed as arbitrary
units and normalized to GAPDH expression.
Immunohistochemical analysis
A single expert pathologist unaware of gene expression
data evaluated all specimens. NPC1L1 intracellular and
plasma membrane (PM) localization were detected by
immunohistochemistry on paraffin-embedded tissue
samples using the antibody (Rabbit Polyclonal anti-Nie-
mann-Pick type C1 Like-1, Novus Biologicals, Inc., Little-
ton, CO, USA) in all subjects. Sections (5 μm thick) were
obtained from formalin-fixed, paraffin-embedded speci-
m e n s .B r i e f l y ,t i s s u es a m p l es were deparaffinized and
hydrated, treated with citrate buffer (0.01 mol/l, pH 6) to
unmask antigens, and treated with 3% H2O2 to block
endogenous peroxidase. Samples were then incubated
with the primary antibody at 1:50 dilution and washed.
The reaction was performed using the EnVision Dako
system (Dako, Milan, Italy) and developed by 3’,3’-diami-
nobenzidine (DAB). Pre-immune rabbit serum, instead of
primary antibody, was used as a negative control, since
there was no signal. A positive reaction was indicated by
a reddish-brown precipitate in the cytoplasm or PM.
Sections were viewed with a Nikon ECLIPSE E600
microscope (Nikon, Japan) using 10×, 20× and 40×
objective lenses, and images were acquired with a SPOT
INSIGHT™ digital colour camera, model 3.2.0 (Sterling
Heights, MI). Quantification of immunoreactivity was
performed on digitally captured colour images saved as
tiff files and analysed using ImageJ 1.37 http://rsb.info.
nih.gov/ij as described previously [17].
Statistical Method
All data are expressed as means ± SD. Statistically sig-
nificant differences between groups were assessed by the
Student’s t-test, Mann-Whitney U test, and correlations
were performed by Pearson’s test. Statistical analyses
were performed using SPSS 11.0 for Windows (SPSS;
Chicago, IL). Statistical significance was defined as a 2-
tailed probability of less than .05.
Results
Clinic characteristics and plasma lipids
D e m o g r a p h i cd a t af o rf e m a l eG Sa n df e m a l eG S Fa r e
shown in Table 1. No significant differences in age and
body mass index were observed. No differences in
plasma lipids between female GS and female GSF were
present (Table 1).
Biliary lipid composition
As shown in Table 2, in the samples analyzed, a signifi-
cantly greater molar percentage of cholesterol was
present in the bile of the female GS compared with the
female GSF, as well as a significantly greater cholesterol
saturation index (female GS vs. female GSF, 1.09 ± 0.07
vs. 0.70 ± 0.05; P < 0.01). Neither the total bile acids nor
the phospholipids in bile differed between the groups
(Table 2). No differences were found in total biliary lipids
(female GS vs. female GSF, 12.78 ± 1.57 vs. 13.32 ± 1.54
g/dl; P = NS), possibly because we ensured that all of the
female GS had normal gallbladder function.
Hepatic gene mRNA levels
As shown in Fig. 1A, the mRNA levels for the hepatic
NPC1L1 were lower in the female GS compared with
the female GSF (P < 0.01). Interestingly, the expression
of ABCG5, ABCG8 and LXRa, measured as mRNA
abundance, did not differ significantly between female
GS and female GSF, as was also the case for 11 other
genes involved in various aspects of the regulation of
hepatic lipid metabolism (Fig. 1A).
A strong positive correlation between hepatic NPC1L1
and SREBP2 mRNA expression was present (r = 0.86, P <
0.01) (Fig. 1B), suggesting that SREBP2 may be an impor-
tant regulator of the hepatic expression of NPC1L1 in
humans. NPC1L1 expression also correlated negatively
with the biliary cholesterol molar percentage (r = -0.73, P
< 0.01) and the CSI (r = -0.76, P < 0.01) (data not shown).
Table 1 Age, body mass index, and plasma lipids of
female GS and female GSF
Variable Female GS (n = 57) Female GSF (n = 12)
Age (years) 47.3 ± 14.2 48.6 ± 16.6
Body mass index (kg/m
2) 22.8 ± 1.3 22.09 ± 2.2
Cholesterol (mmol/l) 4.18 ± 0.37 4.13 ± 0.46
Triglyceride (mmol/l) 1.68 ± 0.26 1.79 ± 0.17
HDL (mmol/l) 1.17 ± 0.06 1.18 ± 0.08
LDL (mmol/l) 2.23 ± 0.22 2.16 ± 0.25
Apolipoprotein A-I (g/l) 1.21 ± 0.06 1.19 ± 0.09
Apolipoprotein B (g/l) 0.71 ± 0.05 0.72 ± 0.06
GS, gallstone patients; GSF, gallstone-free controls.
Table 2 Biliary lipid composition in female GS and female
GSF
Variable Female GS (n = 57) Female GSF (n = 12)
Cholesterol (mmol/L) 16.76 ± 1.79 11.32 ± 1.06
Phospholipids (mmol/L) 44.06 ± 4.37 52.39 ± 4.58
Bile acids (mmol/L) 131.45 ± 14.56 173.58 ± 15.89
Cholesterol (mol%) 7.96 ± 0.46** 4.78 ± 0.38
Phospholipids (mol%) 22.01 ± 1.07 21.97 ± 0.96
Bile acids (mol%) 71.92 ± 1.23 74.76 ± 1.43
Total biliary lipids (g/dl) 12.78 ± 1.57 13.32 ± 1.54
CSI 1.09 ± 0.07** 0.70 ± 0.05
GS, gallstone patients; GSF, gallstone-free controls; CSI, cholesterol saturation
index; ** female GS vs. female GSF, P < 0.01.
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ABCG5, ABCG8 and LXRa mRNA expression between
female GS and female GSF in our study, we found that
ABCG5 and ABCG8 mRNA levels correlated very well
(r = 0.69, P < 0.01) (Fig. 1C), confirming their likely
coexpression in human liver in vivo, as we previously
have observed in liver tissue [5]. Because LXRa are
known to regulate ABCG5/ABCG8, these genes were
used as controls of our model; also, we tested the corre-
lation between LXRa and ABCG5/ABCG8. In agreement
with previous studies, we found that LXRa correlated
with both ABCG5 (r = 0.67, P < 0.01) (Fig. 1D) and
ABCG8 (r = 0.50, P < 0.01) (Fig. 1E) mRNA levels.
NPC1L1 protein expression correlate with the mRNA
levels
To determine whether decreased NPC1L1 mRNA levels
translated into decreased activity, we analyzed the rela-
tionship between normalized mRNA and protein levels.
We observed a significant correlation between NPC1L1
mRNA and protein levels (n = 18, r = 0.84, P < 0.01)
(Fig. 2A).
NPC1L1 displayed lower levels of mRNA in female GS
compared with female GSF (P < 0.01) (Fig. 1A). This
was paralleled by decrease of the NPC1L1 protein (P <
0.01), NPC1L1 protein levels were lower in female
patients with gallstone disease than in those without
gallstone disease (Fig. 2B and Fig. 2C).
NPC1L1 location and expression in hepatocytes by
immunohistochemistry
After subtracting the non-white background colour, the
haematoxylin component was separated from the DAB
component using colour deconvolution as described
[18] (Fig. 3A-C). For each specimen, the lowest and the
highest mean optical density (MOD) values measured
from eight manually identified positively stained cells
selected from the DAB component (with visual
Figure 1 Quantitative mRNA expression levels in genes from the liver in female gallstone patients (GS) and female gallstone-free
patients (GSF). A: Relative gene expression between female GS (n = 57) and female GSF (n = 12). The dotted line at value 1 represents the
mean gene expression level in female GSF, which was arbitrarily set to 1 (A.U.); the black bars represent the gene expression levels in female GS
(means ± SD). B: Correlation between hepatic NPC1L1 and SREBP2 mRNA levels (n = 69). C: Correlation between hepatic ABCG5 and ABCG8
mRNA levels (n = 69). D: Correlation between hepatic LXRa and ABCG5 mRNA levels (n = 69). E: Correlation between hepatic LXRa and ABCG8
mRNA levels (n = 69).
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t h r e s h o l dm a n u a l l yf o rw h o l es a m p l es t a i n i n gd e n s i t y
quantification (Fig. 3D). Comparison of panels A and D
indicates that NPC1L1 is expressed in both the cyto-
plasm and PM of the hepatocytes.
Quantitative immunohistochemistry (Fig. 4A, B) was
performed to compare hepatic NPC1L1 expression
between female GS and female GSF. The mean area of
the evaluated specimens, measured in square pixels, did
not vary significantly between the two groups (female
GS, 1 112 900 ± 171 037; female GSF, 1 156 300 ± 159
485 (P > 0.05)). There was a trend towards a lower
mean percentage area showing NPC1L1 positivity in the
female GS samples (5.4 ± 2.1%) compared with female
GSF samples (12.9 ± 4.2%) (Fig. 4A, B), and the differ-
ence was statistically significant (P < 0.01). The NPC1L1
immunohistochemical MOD differed significantly (P <
0.05) between the female GS (0.33 ± 0.05) and female
GSF (0.54 ± 0.07).
Discussion
In order to identify the molecular defects in the pathogen-
esis of cholesterol gallstone disease, many previous studies
have been carried out in animal models and have not been
evaluated in humans. The present study is one of the first
approaches to utilize liver biopsies to evaluate differences
in gene expression between female patients with and with-
out cholesterol gallstone disease. Our results confirm and
extend findings in animal models, indicating that
decreased hepatic NPC1L1 activity may play a role in the
pathogenesis of gallstone disease in female.
Although cholesterol gallstone disease is a multifactor-
ial disease influenced by a complex interaction of
genetic and environmental factors [19], hepatic hyperse-
cretion of biliary cholesterol is the primary defect in the
formation of cholesterol gallstones. Recent studies on
molecular transporters involved in biliary lipid secretion
suggest that the hepatic secretion efficiency of biliary
cholesterol could be regulated by multiple genes at the
Figure 2 Hepatic expression of NPC1L1 protein in female gallstone patients (GS) and female gallstone-free patients (GSF).A :
Correlation between NPC1L1 mRNA and protein levels in 18 female subjects (P < 0.01). AU, arbitrary units. B: NPC1L1 protein expression in
female patients with gallstone disease (n = 11), and without gallstone disease (n = 7). GAPDH is shown as a control. R represents a human liver
membrane sample that was used as a reference for each gel. C: NPC1L1 protein level was lower in female GS than in female GSF. Data show
means ± SD of the value obtained from the quantitation of the blots shown in 2B. A.U., arbitrary units.
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dent and independent pathways [20]. Moreover, recent
progress in understanding the molecular basis of hepatic
sterol transporters has strongly suggested an ABCG5/
ABCG8-independent pathway for hepatic secretion of
biliary cholesterol and its role in the formation of cho-
lesterol gallstones [20].
The NPC1L1 protein shares 42% identity and 51%
similarity with NPC1 [12].N P C 1 L 1i sa b u n d a n t l y
expressed in both the small intestine and liver of
humans and localizes at the canalicular membrane of
hepatocytes [9,10,21]. The canalicular expression of
NPC1L1 in the liver resulted in a drastic reduction in
biliary cholesterol concentration in 2 independent
transgenic mouse lines [9], indicating that liver
NPC1L1 may mediate biliary cholesterol reabsorption.
However, little is known about the real role of hepatic
NPC1L1 expression in gallstone disease in humans. In
another study made by us, no difference was found for
the hepatic NPC1L1 mRNA levels between Chinese
male GS (n = 30) and male GSF (n = 15) (data not
shown). Interestingly, in our present study, decreased
NPC1L1 mRNA and protein levels have been observed
in the liver in female patients with gallstone disease,
also suggesting possible similarity between transcrip-
tional and translational actions in this hepatic choles-
terol transporter. Further more, immunohistochemical
evaluation supports this conclusion by showing
Figure 3 Quantitative immunohistochemistry to detect NPC1L1 from a specimen from a female gallstone-free control using ImageJ.
After stripping the original digital image of non-white background (A), colour deconvolution is used to separate the haematoxylin component
(B) from the 3’,3’-diaminobenzidine (DAB) component (C). The minimum and maximum mean optical density values of eight positively stained
cells selected from the DAB analysis are used to set the threshold manually (D) for sample optical density measurement. original magnification
40×.
Cui et al. Lipids in Health and Disease 2010, 9:17
http://www.lipidworld.com/content/9/1/17
Page 6 of 9decreased NPC1L1 hepatocellular staining in female
patients with gallstone disease.
We did not observe any differences in plasma lipids
between female GS and female GSF, an observation con-
sistent with our previous studies in Chinese gallstone
patients [5,22]. In our study, we found that a signifi-
cantly greater molar percentage of biliary cholesterol
and an increased CSI occurred in Chinese female gall-
stone patients. Moreover, we found hepatic NPC1L1
expression level also correlated negatively with the bili-
ary cholesterol molar percentage and the CSI, which
suggest the relationship between the expression level of
hepatic NPC1L1 and biliary cholesterol secretion in
humans. The functional impact of lower hepatic
NPC1L1 expression in our female GS patients is difficult
to estimate directly, but it could signify decreased biliary
cholesterol reabsorption in the liver. This is also the
first study to characterize such function for NPC1L1 in
humans.
Some previous studies have shown that NPC1L1 loca-
lizes on the PM [10,23] or in intracellular compartments
[13,14]. Recent study found that NPC1L1 recycles
between endocytic recycling compartment (ERC) and
PM, and the subcellular localization of NPC1L1 protein
is regulated by cholesterol [24]. Cholesterol-depletion
induces the translocation of NPC1L1 from ERC to PM,
the NH2-terminus of NPC1L1 with a predicted signal
peptide faces the extracellular matrix and the COOH-
terminus projects to the cytosol [25], whereas replenish-
ment of cholesterol results in the transportation of
NPC1L1 from PM to ERC [24]. ERC is a component of
the endocytic recycling system [26], NPC1L1 is in the
Figure 4 Presence of hepatic NPC1L1 in female gallstone patients (GS) and female gallstone-free patients (GSF).T i s s u e sw e r e
immunohistochemically stained for NPC1L1 (A, B). Hepatic specimens shown are from female GS (A) and female GSF (B). Panel C shows results
in the absence of primary antibody for NPC1L1. Panels A, B are superimposed with optical density results (red colour) derived from ImageJ. All
samples were counterstained with haematoxylin; original magnification 10× (A, B) and 40× (C).
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NPC1L1 pool exists at the cell interior [27], consistent
with our findings on NPC1L1 hepatocellular staining by
immunohistochemistry.
Sterol regulatory element binding proteins (SREBPs) are
transcription factors that are crucial regulators of choles-
terol homeostasis [28]. Previous study found that in
SREBP-1a, -1c, and -2 isoforms of this family of transcrip-
tion factors, SREBP2 is the major regulator of the human
NPC1L1 promoter [29]. And SREBP2 seems to be an
important regulator of both the intestinal and the hepatic
NPC1L1 expression in humans [29,30]. Our present study
also showed a strong positive correlation between
NPC1L1 and SREBP2 mRNA expression in liver from Chi-
nese female patients with and without gallstone, which
suggests that SREBP2 may be an important regulator of
the hepatic expression of NPC1L1 in humans, in agree-
ment with our previous report [30].
ABCG5 and ABCG8 appear to function as a heterodi-
mer for the secretion of cholesterol into the bile canali-
culus [31]. ABCG5/ABCG8 are direct target genes of
the oxysterol-activated nuclear receptor LXRa [32,33].
In our previous study, we found higher levels of hepatic
ABCG5/ABCG8 and LXRa mRNA in gallstone patients
[5], which could cause higher amounts of cholesterol to
be delivered into the bile. Interestingly, in the present
study, no differences were observed between female
patients and controls for the hepatic ABCG5/ABCG8
and LXRa mRNA expression, suggesting that gallstone
disease is a multifactorial disease that is influenced by
multiple genes. And we thought besides gender, the
selection of the types of gallstone-free patients is an
important reason for this discrepancy. In our present
study and in the previous study, the gallstone-free con-
trols were quite different. In our previous study, the
majority of the patients enrolled in the gallstone-free
controls were patients with gallbladder polyps. In the
present study, the patients enrolled in the gallstone-free
controls underwent surgical procedures because of right
hepatic hemangioma or early carcinoma of head of pan-
creas, they all had perfectly normal gallbladder function.
However, in our female GS and GSF, we also showed
a strong positive relationship between ABCG5 and
ABCG8 mRNA expression levels, and ABCG5/ABCG8
also correlated with LXRa expression, consistent with
these possibilities that in human liver, ABCG5 and
ABCG8 are partners in the generation of a functional
transporter, and ABCG5/ABCG8 are transcriptionally
regulated by LXRa. Moreover, our female gallstone
patients did not show any differences in the hepatic
mRNA expressions of ABCB4, ABCB11, FXR and other
genes participating in the hepatic lipid metabolism, in
agreement with our previous study [5].
Our observation suggests that the hepatic NPC1L1
may be an important, selective target for the treatment
of cholesterol gallstones in female. However, further
studies are required to elucidate why decreased
NPC1L1 expression occurred in female patients with
gallstones, but not male gallstone patients (data not
show). Furthermore, the relatively small sample size
and the lack of prospective evaluation suggest caution
in interpreting our result. And we consider that any
conclusion regarding the exact role of NPC1L1 in cho-
lesterol metabolism and transport should be appropri-
ately interpreted and will also require further
characterization.
In conclusion, in our study of normolipidemic, nonob-
ese Chinese female gallstone patients, the supersatura-
tion of the bile with cholesterol was associated with a
decreased expression of hepatic NPC1L1, which was
possibly mediated by hepatic SREBP2. The current
result also suggests that to regulate hepatic NPC1L1
expression could represent a novel strategy for the pre-
vention of cholesterol gallstones in female.
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